- Home
- GPOR vs BDTX Comparison
GPOR vs BDTX Comparison
Compare GPOR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPOR | BDTX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 104.0M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GPOR | BDTX |
|---|---|---|
| Price | $164.99 | $1.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $213.38 | $10.00 |
| AVG Volume (30 Days) | 273.3K | ★ 581.2K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 245.92 | 130.71 |
| EPS | ★ 13.82 | N/A |
| Revenue | ★ $1,422,583,000.00 | N/A |
| Revenue This Year | $15.27 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.77 | ★ N/A |
| Revenue Growth | ★ 48.47 | N/A |
| 52 Week Low | $149.18 | $1.60 |
| 52 Week High | $225.78 | $4.94 |
Technical Indicators
Market Signals| Indicator | GPOR | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 36.51 |
| Support Level | $158.91 | $1.61 |
| Resistance Level | $171.91 | $1.90 |
| Average True Range (ATR) | 3.96 | 0.08 |
| MACD | 1.37 | -0.01 |
| Stochastic Oscillator | 95.60 | 2.50 |
Price Performance
Historical ComparisonAbout GPOR Gulfport Energy Corporation
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets located in the Appalachia and Anadarko basins in the United States. The principal properties of the company are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.